Liangwei Wang

Pyramid Vision Transformer: A Versatile Backbone for Dense Prediction without Convolutions

Cutting Edge: Antimalarial Drugs Inhibit IFN-β Production through Blockade of Cyclic GMP-AMP Synthase–DNA Interaction

Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review

Single-cell transcriptome landscape of circulating CD4+ T cell populations in autoimmune diseases

Rheumatoid arthritis

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Hydroxychloroquine: From Malaria to Autoimmunity

Systemic lupus erythematosus

Macrophages in immunoregulation and therapeutics

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?

Photosensitivity, Apoptosis, and Cytokines in the Pathogenesis of Lupus Erythematosus: a Critical Review

Emerging concepts of type I interferons in SLE pathogenesis and therapy

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

The JAK/STAT signaling pathway: from bench to clinic

The emerging safety profile of JAK inhibitors in rheumatic disease

IRF3 and type I interferons fuel a fatal response to myocardial infarction

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Systemic lupus erythematosus

Ulcerative colitis

Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells

Mitochondria as multifaceted regulators of cell death

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Extracellular DNA traps in inflammation, injury and healing

NF-κB, inflammation, immunity and cancer: coming of age

Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19

Effect of Impaired T Cell Receptor Signaling on the Gut Microbiota in a Mouse Model of Systemic Autoimmunity

Repurposing approved drugs on the pathway to novel therapies

Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus

Drugs for discoid lupus erythematosus

2015 ESC Guidelines for the management of infective endocarditis

Differential Responsiveness of Monocyte and Macrophage Subsets to Interferon

PAN++: Towards Efficient and Accurate End-to-End Spotting of Arbitrarily-Shaped Text

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

ABCNet: Real-Time Scene Text Spotting With Adaptive Bezier-Curve Network

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus